Anne Marie Furney net worth and biography

Anne Furney Biography and Net Worth

General Counsel of Takeda Pharmaceutical

Natalie Furney is global general counsel for Takeda. She joined Takeda in April 2025.

Before joining Takeda, Natalie held various strategic leadership roles at Eli Lilly and Company, most recently as senior vice president and deputy general counsel, where she provided strategic legal counsel to the International Business Unit and Regulatory leadership teams. Natalie also partnered with Ethics & Compliance, HR and Finance to enhance risk mitigation strategies and led the International Legal and Regulatory Legal teams, developing talent and driving organizational excellence.

Natalie’s 14-year career at Lilly included transforming the Litigation, Investigations and HR Legal teams, as well as leading cross-functional issue management teams in crisis situations. Her leadership resulted in best-in-class legal strategies for the organization.

Natalie holds a Juris Doctor from Valparaiso University School of Law and a bachelor’s degree in journalism and political science from Indiana University - Bloomington. She is admitted to the Indiana Bar and the United States District Court, Southern District of Indiana.

Natalie’s commitment to continuous improvement and talent development is reflected in her recent activities, including co-chairing the ACI Trade Sanctions Compliance Conference and serving on the Board and Executive Committee of the Indianapolis Symphony Orchestra.

Natalie lives in the Boston area with her husband and two children.

What is Anne Marie Furney's net worth?: The estimated net worth of Anne Marie Furney is at least $3.56 million as of August 10th, 2026. Furney owns 204,298 shares of Takeda Pharmaceutical stock worth more than $3,561,936 as of August 13th. This net worth evaluation does not reflect any other assets that Furney may own. Learn More about Anne Marie Furney's net worth.
How do I contact Anne Marie Furney?: The corporate mailing address for Furney and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Anne Marie Furney's contact information.
Has Anne Marie Furney been buying or selling shares of Takeda Pharmaceutical?: During the last ninety days, Anne Marie Furney has sold $527,842.80 in Takeda Pharmaceutical stock. Most recently, Natalie Anne Marie Furney sold 30,868 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $527,842.80. Following the completion of the sale, the general counsel now directly owns 204,298 shares of the company's stock, valued at $3,493,495.80. Learn More on Anne Marie Furney's trading history.
Who are Takeda Pharmaceutical's active insiders?: Takeda Pharmaceutical's insider roster includes Lauren Duprey (Chief Transformation Officer), Samaan Farajallah (Insider), Anne Furney (General Counsel), Deidre Greenway (Insider), Riad Ibrahim (Insider), Julie Kim (Representative Director – President and CEO), Agosti Pignagnoli (Insider), Giles Platford (President, International Business Unit), Gabriele Ricci (Insider), and Elaine Shannon (President, Global Supply & Quality). Learn More on Takeda Pharmaceutical's active insiders.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 444,100 shares worth more than $7,594,110.00. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Anne Marie Furney Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	30,868	$17.10	$527,842.80	204,298

Anne Marie Furney Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.38

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

378,150 shs

Average Volume

3,167,810 shs

Market Capitalization

$55.80 billion

P/E Ratio

51.22

Dividend Yield

2.75%

Beta

N/A